Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2020

Open Access 01-12-2020 | Irritable Bowel Syndrome | Research article

Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction

Authors: Changrong Zhang, Yongquan Huang, Peiwu Li, Xinlin Chen, Fengbin Liu, Qiuke Hou

Published in: BMC Complementary Medicine and Therapies | Issue 1/2020

Login to get access

Abstract

Background

Ginger or ginger extracts have been used in traditional medicine relieve pain caused by diarrhea predominant irritable bowel syndrome (IBS-D), but few data exists about its effectiveness. This present study was to validate the effect of ginger on visceral pain, and to further explore the possible underlying mechanism by which ginger is used to relieve IBS-D intestinal hypersensitivity.

Methods

First, the IBS-D rat model was established by chemical stimulation and acute and chronic pressure stimulation. Then, different dose of ginger were administrated to IBS-D rats and evaluate the defecation frequency, fecal water content (FWC) and abdominal withdrawal reflex (AWR) scores in IBS-D rats. Further, the IBS-D rats were sacrificed to collecte the colonic tissues to evaluate the effect of ginger administration on its pathology and changes of pro-inflammatory factors, and changes of NF-κB pathway. Second, the ginger was taken to HPLC analysis and 6-gingerol was choosen to further experiment. Then, IBS-D rats were treated with different dose of 6-gingerol, and the behavioral evaluation were to evaluate the effect of 6-gingerol on IBS-D rats. Further, colonic epithelial cells (CECs) were collectted and to evaluate the effect of 6-gingerol on the expression of inflammatory factors and changes of NF-κB pathway.

Results

The IBS-D rat model was successfully established by chemical stimulation and acute and chronic pressure stimulation. And ginger treatment significantly reduced the defecation frequency, fecal water content and AWR scores in IBS-D rats. Histopathological analysis showed that ginger treatment can significantly reduce colonic edema and promote the recovery of inflammation in IBS-D rats, and the effect is equivalent to rifaximin. Elisa and RT-qPCR showed that ginger inhibited the expression of proinflammatory factors (TNF-α, IL-6, iNOS) in IBS-D rats. Western blot showed IkBα was up-regulated while p-p65 was inhibited under ginger treatment. HPLC analysis showed that 6-gingerol was the main component of ginger, which could improve clinical symptoms in IBS-D rats. Western blot and RT-qPCR showed that 6-gingerol inhibited the expression of proinflammatory factors (TNF-α, IL-6, iNOS) in CECs, and inhibition of IκBα degradation and phosphorylation of p65 involved in NF-κB pathway.

Conclusion

Ginger and ginger extract could relieve intestinal hypersensitivity of IBS-D by inhibiting proinflammatory response.
Appendix
Available only for authorised users
Literature
1.
go back to reference Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. 2018;67(6):1078–86.CrossRef Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. 2018;67(6):1078–86.CrossRef
2.
go back to reference Coeffier M, Dechelotte P, Ducrotte P. Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation? Gastroenterology. 2015;148(5):1079–80.CrossRef Coeffier M, Dechelotte P, Ducrotte P. Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation? Gastroenterology. 2015;148(5):1079–80.CrossRef
3.
go back to reference Gracie DJ, Ford AC. Irritable bowel syndrome-type symptoms are associated with psychological comorbidity, reduced quality of life, and health care use in patients with inflammatory bowel disease. Gastroenterology. 2017;153(1):324–5.CrossRef Gracie DJ, Ford AC. Irritable bowel syndrome-type symptoms are associated with psychological comorbidity, reduced quality of life, and health care use in patients with inflammatory bowel disease. Gastroenterology. 2017;153(1):324–5.CrossRef
4.
go back to reference Sun J, Wu X, Meng Y, Cheng J, Ning H, Peng Y, et al. Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of diarrhea-predominant irritable bowel syndrome(D-IBS). BMC Complement Altern Med. 2015;15:340.CrossRef Sun J, Wu X, Meng Y, Cheng J, Ning H, Peng Y, et al. Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of diarrhea-predominant irritable bowel syndrome(D-IBS). BMC Complement Altern Med. 2015;15:340.CrossRef
5.
go back to reference Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with Rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113–21.CrossRef Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with Rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113–21.CrossRef
6.
go back to reference Lembo A, Rao SSC, Heimanson Z, Pimentel M. Abdominal pain response to Rifaximin in patients with irritable bowel syndrome with diarrhea. Clin Transl Gastroenterol. 2020;11(3):e00144.CrossRef Lembo A, Rao SSC, Heimanson Z, Pimentel M. Abdominal pain response to Rifaximin in patients with irritable bowel syndrome with diarrhea. Clin Transl Gastroenterol. 2020;11(3):e00144.CrossRef
7.
go back to reference van Tilburg MA, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med. 2008;8:46.CrossRef van Tilburg MA, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med. 2008;8:46.CrossRef
8.
go back to reference Srivastava KC, Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses. 1992;39(4):342–8.CrossRef Srivastava KC, Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses. 1992;39(4):342–8.CrossRef
9.
go back to reference Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum. 2001;44(11):2531–8.CrossRef Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum. 2001;44(11):2531–8.CrossRef
10.
go back to reference Park M, Bae J, Lee DS. Antibacterial activity of [10]-gingerol and [12]-gingerol isolated from ginger rhizome against periodontal bacteria. Phytotherapy research : PTR. 2008;22(11):1446–9.CrossRef Park M, Bae J, Lee DS. Antibacterial activity of [10]-gingerol and [12]-gingerol isolated from ginger rhizome against periodontal bacteria. Phytotherapy research : PTR. 2008;22(11):1446–9.CrossRef
11.
go back to reference Young HY, Luo YL, Cheng HY, Hsieh WC, Liao JC, Peng WH. Analgesic and anti-inflammatory activities of [6]-gingerol. J Ethnopharmacol. 2005;96(1–2):207–10.CrossRef Young HY, Luo YL, Cheng HY, Hsieh WC, Liao JC, Peng WH. Analgesic and anti-inflammatory activities of [6]-gingerol. J Ethnopharmacol. 2005;96(1–2):207–10.CrossRef
12.
go back to reference Tian L, Qian W, Qian Q, Zhang W, Cai X. Gingerol inhibits cisplatin-induced acute and delayed emesis in rats and minks by regulating the central and peripheral 5-HT, SP, and DA systems. J Nat Med. 2020;74(2):353–70.CrossRef Tian L, Qian W, Qian Q, Zhang W, Cai X. Gingerol inhibits cisplatin-induced acute and delayed emesis in rats and minks by regulating the central and peripheral 5-HT, SP, and DA systems. J Nat Med. 2020;74(2):353–70.CrossRef
13.
go back to reference Borrelli F, Capasso R, Aviello G, Pittler MH, Izzo AA. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol. 2005;105(4):849–56.CrossRef Borrelli F, Capasso R, Aviello G, Pittler MH, Izzo AA. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol. 2005;105(4):849–56.CrossRef
14.
go back to reference Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S, Leeprakobboon K, Leelasettagool C. The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am J Obstet Gynecol. 2006;194(1):95–9.CrossRef Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S, Leeprakobboon K, Leelasettagool C. The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am J Obstet Gynecol. 2006;194(1):95–9.CrossRef
15.
go back to reference Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci. 2005;50(10):1889–97.CrossRef Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci. 2005;50(10):1889–97.CrossRef
16.
go back to reference Terry R, Posadzki P, Watson LK, Ernst E. The use of ginger (Zingiber officinale) for the treatment of pain: a systematic review of clinical trials. Pain Med. 2011;12(12):1808–18.CrossRef Terry R, Posadzki P, Watson LK, Ernst E. The use of ginger (Zingiber officinale) for the treatment of pain: a systematic review of clinical trials. Pain Med. 2011;12(12):1808–18.CrossRef
17.
go back to reference Singh AK, Zajdel J, Mirrasekhian E, Almoosawi N, Frisch I, Klawonn AM, et al. Prostaglandin-mediated inhibition of serotonin signaling controls the affective component of inflammatory pain. J Clin Invest. 2017;127(4):1370–4.CrossRef Singh AK, Zajdel J, Mirrasekhian E, Almoosawi N, Frisch I, Klawonn AM, et al. Prostaglandin-mediated inhibition of serotonin signaling controls the affective component of inflammatory pain. J Clin Invest. 2017;127(4):1370–4.CrossRef
18.
go back to reference Grabauskas G, Wu X, Gao J, Li JY, Turgeon DK, Owyang C. Prostaglandin E2, produced by mast cells in Colon tissues from patients with irritable bowel syndrome. Gastroenterology: Contributes to Visceral Hypersensitivity in Mice; 2020. Grabauskas G, Wu X, Gao J, Li JY, Turgeon DK, Owyang C. Prostaglandin E2, produced by mast cells in Colon tissues from patients with irritable bowel syndrome. Gastroenterology: Contributes to Visceral Hypersensitivity in Mice; 2020.
19.
go back to reference Bando T, Fujita S, Nagano N, Yoshikawa S, Yamanishi Y, Minami M, et al. Differential usage of COX-1 and COX-2 in prostaglandin production by mast cells and basophils. Biochem Biophys Rep. 2017;10:82–7.PubMedPubMedCentral Bando T, Fujita S, Nagano N, Yoshikawa S, Yamanishi Y, Minami M, et al. Differential usage of COX-1 and COX-2 in prostaglandin production by mast cells and basophils. Biochem Biophys Rep. 2017;10:82–7.PubMedPubMedCentral
20.
go back to reference Hwang YH, Kim T, Kim R, Ha H. The Natural Product 6-Gingerol Inhibits Inflammation-Associated Osteoclast Differentiation via Reduction of Prostaglandin E (2) Levels. Int J Mol Sci. 2018;19:7. Hwang YH, Kim T, Kim R, Ha H. The Natural Product 6-Gingerol Inhibits Inflammation-Associated Osteoclast Differentiation via Reduction of Prostaglandin E (2) Levels. Int J Mol Sci. 2018;19:7.
21.
go back to reference Hou Q, Huang Y, Zhu S, Li P, Chen X, Hou Z, et al. MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1. Cell Physiol Biochem. 2017;44(6):2256–68.CrossRef Hou Q, Huang Y, Zhu S, Li P, Chen X, Hou Z, et al. MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1. Cell Physiol Biochem. 2017;44(6):2256–68.CrossRef
22.
go back to reference Hou Q, Huang Y, Zhang C, Zhu S, Li P, Chen X, et al. MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral Hyperalgesia in diarrhea-predominant irritable bowel syndrome rats. J Neurogastroenterology Motility. 2018;24(4):656–68.CrossRef Hou Q, Huang Y, Zhang C, Zhu S, Li P, Chen X, et al. MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral Hyperalgesia in diarrhea-predominant irritable bowel syndrome rats. J Neurogastroenterology Motility. 2018;24(4):656–68.CrossRef
23.
go back to reference Hou Q, Huang Y, Zhu Z, Liao L, Chen X, Han Q, et al. Tong-Xie-Yao-fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-kappaB and notch signalling pathways. BMC Complement Altern Med. 2019;19(1):337.CrossRef Hou Q, Huang Y, Zhu Z, Liao L, Chen X, Han Q, et al. Tong-Xie-Yao-fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-kappaB and notch signalling pathways. BMC Complement Altern Med. 2019;19(1):337.CrossRef
24.
go back to reference American GA. Irritable bowel syndrome in adults (IBS-D): clinical decision support tool. Gastroenterology. 2019;157(3):855.CrossRef American GA. Irritable bowel syndrome in adults (IBS-D): clinical decision support tool. Gastroenterology. 2019;157(3):855.CrossRef
25.
go back to reference Simren M, Tornblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J. Cumulative effects of Psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology. 2019;157(2):391–402 e392.CrossRef Simren M, Tornblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J. Cumulative effects of Psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology. 2019;157(2):391–402 e392.CrossRef
26.
go back to reference Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(6):e13819.CrossRef Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(6):e13819.CrossRef
27.
go back to reference Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, McDonald T, Spreadbury I, Cenac N, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology. 2011;141(6):2098–108 e2095.CrossRef Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, McDonald T, Spreadbury I, Cenac N, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology. 2011;141(6):2098–108 e2095.CrossRef
28.
go back to reference Schmidt T, Pfeiffer A, Kaess H. Abnormal intestinal motility in irritable bowel syndrome. Gastroenterology. 1996;111(5):1400–1.CrossRef Schmidt T, Pfeiffer A, Kaess H. Abnormal intestinal motility in irritable bowel syndrome. Gastroenterology. 1996;111(5):1400–1.CrossRef
29.
go back to reference Dai C, Jiang M, Sun MJ. Rifaximin in the treatment of patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2017;152(6):1629–30.CrossRef Dai C, Jiang M, Sun MJ. Rifaximin in the treatment of patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2017;152(6):1629–30.CrossRef
30.
go back to reference Tavlan A, Tuncer S, Erol A, Reisli R, Aysolmaz G, Otelcioglu S. Prevention of postoperative nausea and vomiting after thyroidectomy: combined antiemetic treatment with dexamethasone and ginger versus dexamethasone alone. Clin Drug Invest. 2006;26(4):209–14.CrossRef Tavlan A, Tuncer S, Erol A, Reisli R, Aysolmaz G, Otelcioglu S. Prevention of postoperative nausea and vomiting after thyroidectomy: combined antiemetic treatment with dexamethasone and ginger versus dexamethasone alone. Clin Drug Invest. 2006;26(4):209–14.CrossRef
31.
go back to reference Blumenthal M. Ginger as an antiemetic during pregnancy. Altern Ther Health Med. 2003;9(1):19–21 author reply 19-21.PubMed Blumenthal M. Ginger as an antiemetic during pregnancy. Altern Ther Health Med. 2003;9(1):19–21 author reply 19-21.PubMed
32.
go back to reference Kiuchi F, Shibuya M, Sankawa U. Inhibitors of prostaglandin biosynthesis from ginger. Chem Pharmaceutical Bull. 1982;30(2):754–7.CrossRef Kiuchi F, Shibuya M, Sankawa U. Inhibitors of prostaglandin biosynthesis from ginger. Chem Pharmaceutical Bull. 1982;30(2):754–7.CrossRef
33.
go back to reference Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344–62.CrossRef Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344–62.CrossRef
34.
go back to reference Kunnumakkara AB, Shabnam B, Girisa S, Harsha C, Banik K, Devi TB, et al. Inflammation, NF-kappaB, and chronic diseases: how are they linked? Crit Rev Immunol. 2020;40(1):1–39.CrossRef Kunnumakkara AB, Shabnam B, Girisa S, Harsha C, Banik K, Devi TB, et al. Inflammation, NF-kappaB, and chronic diseases: how are they linked? Crit Rev Immunol. 2020;40(1):1–39.CrossRef
35.
go back to reference Chen J, Lobb IT, Morin P, Novo SM, Simpson J, Kennerknecht K, et al. Identification of a novel TIF-IA-NF-kappaB nucleolar stress response pathway. Nucleic Acids Res. 2018;46(12):6188–205.CrossRef Chen J, Lobb IT, Morin P, Novo SM, Simpson J, Kennerknecht K, et al. Identification of a novel TIF-IA-NF-kappaB nucleolar stress response pathway. Nucleic Acids Res. 2018;46(12):6188–205.CrossRef
36.
go back to reference Habelhah H. Emerging complexity of protein ubiquitination in the NF-kappaB pathway. Genes Cancer. 2010;1(7):735–47.CrossRef Habelhah H. Emerging complexity of protein ubiquitination in the NF-kappaB pathway. Genes Cancer. 2010;1(7):735–47.CrossRef
Metadata
Title
Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction
Authors
Changrong Zhang
Yongquan Huang
Peiwu Li
Xinlin Chen
Fengbin Liu
Qiuke Hou
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2020
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-020-03059-3

Other articles of this Issue 1/2020

BMC Complementary Medicine and Therapies 1/2020 Go to the issue